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PHENOMENON
Abstract
Privatization is one of the most significant phenomena and characteristics 
of contemporary science, but also probably its greatest deviation. Through the 
growing funding of research by private companies, science has been increasingly 
used to create profit. It is instrumentalized by being reduced to a marketing tool. 
In medicine today, most of the applied research is sponsored by the producers of 
agents and equipment for diagnostics and treatment. Through the manipulation 
by the methodology of research, result presentation and selective publication, 
they produce findings which are invalid and biased. The topic of research is 
less and less relevant for the health and well-being of the population. With the 
medical science being privatized, the prospects of significant discoveries and 
progress in disease treatment and prevention are slim. A rise of costs is inevitable, 
as well as the decrease in the availability. Along with the privatized medical 
science, the chances for more significant findings and progress in treatment and 
illness prevention are not good. The growth in expenses is apparent, as well as 
the downturn in the availability of healthcare services and the erosion of trust 
in science and scientists.  Privatization of science is a phenomenon which is 
rarely discussed. It deserves greater attention because it can have significant 
consequences on the nature and the excellence of scientific findings and is 
relevant in the social and cultural context. 
Key words: Privatization of science, commercialization of science, 
manipulation of scientific research, conflict of interest in medicine 
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Private sector invests in science  
Countries differ in investing in the scientific research. The data says that 
one of the leading countries of the world, the United States of America, invests 
400 billion dollars a year, the equivalent of 2.7 % GDP. Significantly larger in 
the number of the population, the European Union spends around 80% of that 
amount, or around 300 billion Euros, which is around 2 % of its GDP on average. 
The money that the USA and EU dedicate to research and development (R&D), 
i.e. its portion of the GDP, has grown through the decades. Lately, however, it has 
stagnated. (Kennedy, 2012; Dorsey, de Roulet and Thompson, 2010; Eurostat, 
2017)
The research and development funding come mostly from two sources – 
from the state (the government) and from private companies or individuals. In 
the US, until the 1980s, the portion of public and private money in the funding 
of science was relatively equal. With the setting up of the liberal economic 
doctrine, the private sector gets faster into science and the portion of industrial 
money for research and development increases. In 2009, it was 62 % against 31 % 
from the public sector. Out of all the scientific research, 70.5 % is performed by 
private companies. (Kennedy, 2012) Government investments are being reduced 
in the relative, as well as in the absolute sense. In the five years after 2009, it was 
reduced from 180 to 140 billion dollars per year and it is estimated that this 
trend will continue. (Jahnke, 2015) 
The relationship between the private and the public investment in science is 
even more on the side of the private in Asian economies, such as China, Japan 
and South Korea. Almost three quarters of their total investment in science is 
made by private businesses. (Eurostat, 2017) 
In Europe, the scientific work and the activities of the universities were 
traditionally bound to public funding. Today, 55.3 % of the EU R&D is paid by 
private, and 32.3 % by the public sector. The portion of the funding from public 
sources is being reduced. Aiming to enlarge the global competitiveness of the 
European Union, the European Commission is planning strengthen the ties of 
the public and private sector and to increase private investments in order to 
approximate the structure of investments in science that of the USA and the 
Asian countries. (Eurostat, 2017) 
Economically weak and indebted countries allocate modest resources in 
science. Croatia is even reducing it, the Independent Union for Science and 
High Education warns, and with 0.85 % GDP is not only way below the European 
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average, but even below the average of European transition countries. In such 
circumstances, scientists are more and more dependent on the company money, 
and the Croatian government also encourages the private sector to invest into 
research and development. (Ribić and Kroflin, 2016) 
Even though the “Europe 2020 Strategy” and the “Horizon 2020” predict an 
increase in the total amount of funds dedicated for research and development, 
the European scientific associations, worried with the decline in the resources 
so far and dissatisfied with the amount of planned funds, are asking for 
greater investments into science. (Reillon, 2015) The Association of American 
Universities demands a stop to the reduction of the scientific budget and expects 
greater investments in R&D. In the impoverished circumstances, American 
universities made a priority of finding new sources of funding and are more and 
more turning to the private sector. From 2006 to 2013, the amount of private 
investments into research activities at the Harvard University was tripled. 
(Jahnke, 2015) The scientific research is being separated from institutions and 
privatized by companies or leading researchers.
The basic research, as well as research in the social sciences and humanities, 
have remained primarily in the domain of the state; the business is primarily 
interested in the applied science research. Biomedicine is one of the most 
propulsive ones. Vera-Badillo et al. (2013) refer to the authors who found 
that, in the period of 30 years, the portion of the pharmaceutical industry in 
funding clinical trials with medications (phase III) increased from 24 % to 72 
%. Kidwell et al. (2001) found that between the 1960s and 1990s, the funding 
by manufacturers of the studies with drugs used in the therapy of stroke, was 
increased from 38 % to 68 %.
The public and private sector are essentially different in aims and ethics. In 
the first case, that is the general well-being and welfare of the community. The 
private entrepreneurship, on the other hand, has the primary interest in the 
biggest and fastest possible profit of the owner. That characteristic of the private 
sector brought about an increase in investments in science and has undoubtedly 
benefited the technological and economic growth and development. However, it 
also had negative consequences. 
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Quality of scientific research
These days, it would be expected that the scientific research is characterized 
by methodological excellence and authenticity of findings. However, that is 
not the case. There are frequent distortions at various points in methodology 
and design. In clinical trials in medicine, for instance, the sample of examinees 
is chosen on which it is easiest to confirm an effect or hypothesis, as well as 
a large sample on which even a trivial effect can be proved (Jochmann et al., 
2005; Rochon, 1998); an inadequate randomization is being done, as well as 
inadequate blinding (Hewitt et al., 2005); a comparator is taken with which the 
procedure looks better (Johansen and Gøtzsche, 1999); the loss of examinees 
(loss to follow-up) is neglected (Cranney et al., 2002; Kirsch et al., 2002); the 
study duration is adapted according to results (Jüni, Rutjes and Dieppe, 2002); 
convenient statistical methods are selected (Lang, 2004); surrogate outcomes 
such as blood pressure and blood sugar are measured, not the clinical ones 
such as the incidence of disease and the life expectancy, and are joined into a 
combined outcome. (Fleming and DeMets, 1996; Temple, 1999)
The presentation and interpretation of results is manipulated – a relative 
risk reduction is highlighted, by which the effect of one in a hundred examinees 
is transformed into a 40% effect. (Lang, 2004) In the discussion and in the 
formulating of the conclusion, different manipulative techniques are used 
(exaggeration, minimization, omission, repetition, generalization, diverting 
attention) which are named spin in the reporting of the scientific findings (Vera-
Badillo et al., 2013). Finally, the papers with positive results are more frequently 
published than those with the negative ones, which reflects on the findings of 
the systematic reviews. (Scherer, Langenberg and von Elm, 2007) The scientific 
community has long been aware of these issues and has attempted to overcome 
them, but the achievements are very limited. 
The analyses mostly fail to prove the connection between the source of 
funding and the methodological quality of the scientific papers. The reason is 
probably in the fact that manipulation is subtle and is on a hardly recognizable 
level of research design. How else would one, along with the fact that the private 
sector a priori tests procedures expected to yield a positive result, explain the 
conclusions of several systematic reviews which showed that privately funded 
biomedical research have significantly more frequent findings in favour of the 
sponsor than the research funded from other, mostly public, sources. (Bekelman, 
Li and Gross, 2003; Lexchin et al., 2003; Lundh et al., 2017) The same goes for 
research in other areas, in regard to food products, for instance. (Lesser et al., 
2007; Nestle, 2016) 
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There are scientists, such as the epidemiologist John Ioannidis (2005) and 
former editor of the Lancet journal Richard Horton (2015), who argue that most 
research findings published today are false. A whole series of books has been 
published which criticize contemporary science. (Milloy, 2001; McGarity and 
Wagner, 2008; Goldacre, 2008; Gajski, 2009; Evans et al., 2011) The credibility 
and consistency of the results is weak; there is even a publication dealing with 
contradictory scientific findings - Journal of Contradicting Results in Science. The 
very paradigm of evidence-based medicine (EBM) has seriously been brought 
into question. (Every-Palmer and Howick, 2014) On the basis of the alleged 
efficiency and safety, products and procedures enter the clinical practice and 
then later research refute it and bring about their withdrawal. Products, but also 
reports on research, are being retreated; according to Retraction Watch, even 
several hundred per year. The reasons for withdrawal being various scientific 
errors, but a third is pure fraud. That is where the review process, which is 
considered to be “scripture” in the scientific community, is revealed as a process 
highly prone to superficiality and bias, including corruption. (Retraction Watch, 
2014) 
Distribution of scientific findings
Inadequately done and reviewed papers get published in the scientific 
publications. A lot of valid and innovative ones are being rejected. Nobel prize 
winners Randy Schekman (Schekman, 2013) and Sydney Brenner (Retraction 
Watch, 2014) claim that the leading scientific publications such as Science and 
Nature are destroying science with their culture and politics and are refusing 
the most important, pioneering research which re-examine and challenge the 
ruling theories.
The editorial boards and owners of scientific publications decide on what will 
and will not be published. They are funded in a significant extent by the producers 
of the diagnostic and treatment tools – directly, by way of the advertisements and 
by the purchase of the reprints of the studies, or indirectly through publishers 
and editors tied to the medical industry. (Smith, 2005; Collier, 2009) The Irish 
scientist David Healy (2001) claims that at least half of the papers on medication 
efficiency in the major medical journals, such as BMJ, Lancet and NEJM are 
actually written by pharmaceutical companies. 
The distribution of scientific knowledge – publication of the scientific 
literature, is in private ownership and has lately been turned by the process of 
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merging into an oligopoly of several publishing houses. (Lariviere, Haustein 
and Mongeon, 2015) Thanks to the high subscription fees, which have grown 
three times as much as the price of other goods and services, they are making 
extreme profit; Elsevier has a staggering 34 %. Unjustified, considering they 
get the scientific papers for free and the demand is guaranteed. (Barić et al., 
2017) The movement for open access to scientific papers was supposed to 
correct this, but some publishers saw it coming and are now asking the authors 
to pay for publishing. This brought about a new deviation – the appearance of 
the so-called predator journals, a business model by which their owners make 
money publishing papers of low quality. (Bowman, 2014) Some authors have 
deliberately sent utterly nonsensical papers to such journals and they were 
published. (Retraction Watch, 2013)
The findings of scientific research reach users mostly by way of professional 
education (review articles, lectures, symposiums). In medicine, a significant and 
the most consumed portion of the education of physicians has been taken over 
by the medical industry and turned into the marketing of their products. (Gajski, 
2009: 224-262) Pharmaceutical companies have paid billions of dollars in fines 
for marketing practice frauds. (Groeger, 2014) As for the public, the scientific 
findings reach them by way of media, the owners of which own the companies 
producing the diagnostic and treatment tools as well.
Scientists in a conflict of interest
It has been proven that many scientists published fake papers in the influential 
journals. Scott Reuben published studies on analgesics for almost 13 years, which 
had a massive influence on the global clinical practices. He never performed the 
research. (Borrell, 2009) 
The Japanese scientist Yoshitaka Fujji published more than 180 papers during 
around 20 years in the leading medical publications, mostly regarding anti-
vomiting medication. Most of them were complete fabrication. (Marcus and 
Oransky, 2015) 
Don Poldermans lead experiment with beta-blockers in regard to the 
protection of the heart during surgical procedures. The findings were falsified 
and are connected to thousands of deaths from these medications. (Husten, 
2013) 
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Danish epidemiologist Poul Thorsen is one of the authors of a series of papers 
cited as an argument for the non-existence of a connection between vaccines 
and autism. The studies are a complete forgery and Thorsen is on the arrest 
warrant of the US Department of Health & Human Services for the theft of the 
research money. (Atlanta Business Chronicle, 2011) 
Whether scientists are employees of a pharmaceutical company, contributors 
on the privately funded research or working in the public sector but having 
personal financial ties to companies, a conflict of interest is inevitable. It most 
often results in the choice of personal financial and professional gain, at the 
expense of scientific truth and well-being of society and the patient (Gajski, 
2012). Victims are counted in hundreds of thousands; it is not an estimate, it is a 
calculation based on the findings of the clinical studies. (Gøtzsche, 2013)  
There is another type of scientist whose fate also testifies to the corruption 
of medical science. They lost scientific projects, promotion, and reputation due 
to lack of cooperation with the sponsor companies, a critique of the scientific 
practice and activity which does not match the mainstream and the current 
paradigm. (Schafer, 2004) Even though the basic features of science are freedom 
of thought, discussion, constant re-examination and critique, the system 
discourages it by withholding money for research, refusing to publish papers 
and ignoring findings, and labelling the creative and free-thinking part of the 
scientific community, as well as the critics outside of the scientific institution, as 
incompetent and pseudo-scientist. (Wakefield, 2011) 
The subject of scientific research
When judging a scientific paper, one needs to also consider its subject. How 
much is the question posed by corporate biomedical research relevant for the 
public health and how much do they contribute to improving the health of the 
people? 
The main owner of medical science researches that which pays off in short 
term– patentable agents for treatment appropriate for long-term application in 
large populations, or very expensive treatments for the rare diseases. (Angell, 
2004) The sponsors of the research prove the efficiency of interventions in mild 
disorders and physiological conditions, widening disease boundaries. (Welch, 
Schwartz and Woloshin, 2012) They perform pharmaco-economic studies which 
always prove cost-effectiveness, observational studies which “find” populations at 
risk, epidemiological studies which exaggerate the dimension and significance of 
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commercially interesting diseases or monitor the medication consumption, and 
make a basic research which interprets the pathophysiology of disease in a way 
that fits the sponsor. (Gajski, 2014) They explores the human genome in order 
to explain hereditary diseases, but also to make money on diagnostic tests and 
costly interventions. The procedures for bodily and cognitive “improvement” are 
tested, which are at the edge of perversion, but affordable to the rich minority.
The result? A multitude of redundant medical products and procedures 
(Mandrola, 2016), through the hyperproduction of scientific papers (the 
Medline database alone puts out several thousand new papers per day), among 
which only a small portion satisfies the objective relevance criteria. The large 
majority are trivial, non-inventive, senseless and useless in the social context; 
intended merely for company benefits and for building researchers’ professional 
careers, (Barić et al., 2017; Ioannidis, 2016) while the actual bibliometrics and 
scientometrics deform and erode normal academic hierarchy and the value 
system. (Lariviere, Haustein and Mongeon, 2015; Sindikat visokog obrazovanja i 
znanosti Akademska solidarnost, 2012) 
Scientific endeavour whose goal is the profit of the producers of medical 
technology has little chance of improving the health of people. Investment 
into biomedical research is growing, but the number of new drugs for various 
pathological conditions is stagnating or declining. (Dorsey et al., 2009; The 
Associated Press, 2005) For instance, the antibiotics clinical medicine is crying 
for are not being developed (they are not profitable because of their short-term 
use) (Bach, 2014), and neither are the treatments for Third World diseases (they 
cannot be billed). (Pheage, 2016-2017) Next, the procedures which are tested 
insufficiently are those not related to technology, although being potentially 
effective or proven as such – natural treatments, and non-pharmacological 
therapy and prevention of disease. There is no interest in the harm produced by 
the medical technology which is growing enormously. (Gajski, 2015) The reason 
for this is not only in the fact that there is no profit here for the medical industry, 
but also in the fact that, at the present level of expansion of medical industry, 
curing disease is in the direct confrontation with its priority. Eradication of 
disease reduces the market for medical products. Thus, the aim becomes to 
maintain a disease as chronic and to create artificially new ones. (Gajski, 2014) 
Consequently, the companies are not researching the real causes of disease, 
either those within the biomedical model and dominant paradigms, let alone 
those outside of it. In such circumstances, it is difficult, for instance, to affirm 
the thesis that social circumstances (poverty, inequality, injustice) are one of the 
leading determinants of health. (Kawachi, Kennedy and Wilkinson, 1999) 
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Science as a tool and knowledge as commodity 
Private entrepreneurship has turned a scientific work from the search 
for truth into a marketing tool, an instrument for profit making. A scientific 
paper is acquiring the characteristics of merchandise, by its content and form. 
Designed to show a product in the best possible light, when completed, it gets 
an attractive “package”, it is advertised and delivered to consumers –in medicine, 
the physicians. The corporate PR designs impressive study acronyms and 
arranges premature completion due to the alleged clear benefit. New studies are 
announced in advance and make the front pages of the popular magazines. They 
are presented by celebrities at medical congresses, written about in popular 
magazines and discussed on TV health shows. Just like many ordinary products, 
they have their websites. (Gajski, 2014)
When science is in possession of companies which compete in the market, its 
product i.e. knowledge is no longer available to everyone, but is now considered 
a trade secret. Researchers have limited access to data, they are obliged to 
confidentiality with regards to all aspects of research and are not allowed to 
present the findings until the product is patented. (Bodenheimer, 2000; Healy, 
2003) The owners of scientific journals limit the availability of information with 
high subscription fees. This is all contrary to the principles of scientific ethics and 
free access to knowledge as a public good and clearly slows down the scientific 
and social advancement. (Rosenberg, 1996) 
Commercialization of science has subjected the scientists and scientific 
institutions to the market standards. Once, a good and successful scientist was 
the one with original papers, self-suppression and integrity; nowadays, it is the 
one with the ability of turning knowledge into a profitable product, a man who 
brings money to the university. Scientific work is becoming inseparable from 
entrepreneurship and scientists are being promoted into businessmen. Research 
institutes operate as profit enterprises, academic medical centres as corporations 
the success of which is measured by the number of contracts with the industry. 
(Angell, 2004; Krimsky, 2004) 
We are witnessing a fundamental and far-reaching transformation which is 
setting up a new system of norms, a new ethos, a new scientific and academic 
culture. In the civilization which entrusted science with the search for truth, 
these changes are necessarily reflected on the social and civilization level. 
Privatization and commodification of knowledge takes the epistemological 
character of science away from it. Freedom and autonomy of scientific activity 
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is severely limited. To possess science means to possess the truth and be able 
to use it to moderate the value system and social flows. Economic principles 
and market logic establish the capitalist instead of humanist values. Corporate 
property of science leads to its abuse at the expense of a public good. And in 
many fields of life including medicine and healthcare, leads to a decrease in 
efficiency and justice, to a rise of costs, multiplying of ethical dilemmas and a 
decline of trust in science and scientists. (Krimsky, 2004; Bok, 2004; Sindikat 
visokog obrazovanja i znanosti Akademska solidarnost, 2012)
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PRIVATIZACIJA ZNANOSTI – PREŠUĆENI FENOMEN
Sažetak
Privatizacija je jedan od najznačajnijih fenomena i obilježja suvremene 
znanosti, no vjerojatno i njena najveća devijacija. Kroz rastuće financiranje 
istraživanja od strane privatnih kompanija znanost se sve više koristi za 
stvaranje zarade, odnosno instrumentalizira se svođenjem na marketinški alat. 
U medicini danas većinu primijenjenih istraživanja sponzoriraju proizvođači 
sredstava i opreme za dijagnostiku i liječenje. Kroz manipulaciju metodologijom 
istraživanja, prezentacijom rezultata i selektivnim objavljivanjem proizvode 
nalaze koji su nevaljani i pristrani. Predmet istraživanja sve je manje relevantan 
za zdravlje i dobrobit stanovništva. Uz privatiziranu medicinsku znanost slabi 
su izgledi za značajnija otkrića i napredak u liječenju i sprječavanju bolesti. 
Izvjestan je rast troškova, pad dostupnosti zdravstvenih usluga i urušavanje 
povjerenja prema znanosti i znanstvenicima.  
Ključne riječi: privatizacija znanosti, komercijalizacija znanosti, 
manipulacije znanstvenim istraživanjima, sukob interesa u medicini 
